Related Experiment Video
Updated: Aug 21, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Suramin: potential in acute liver failure
1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.com
Abstract:
Apoptosis is the first cellular response of the liver to many toxic events, including viral hepatitis, alcohol-induced liver disease and ischaemia/reperfusion injury. When apoptosis is induced with an antibody to APO-1, suramin is antiapoptotic in a variety of cell lines (e.g., Jurkat cells, HepG2). Jo2 is an antibody to mouse CD95, which kills C57Bl/6 mice, and was used as a model of fulminant liver failure in mice. Suramin protected 40% of Jo2-treated mice from death and delayed death in the other mice. In mice, D-galactosamine and endotoxin cause apoptotic liver damage, which is mediated by TNF. Suramin reduced this liver damage as assessed by serum aminotransferase levels, gross liver appearance and apoptosis levels. In contrast, suramin does not inhibit necrotic cell death in a rat model of liver transplantation. Inhibition of apoptosis with suramin or other more selective agents is an approach that should be further investigated in liver failure.
Insights
Suramin, an anti-cancer drug, demonstrates protective effects against liver injury by inhibiting apoptosis. This finding suggests suramin
Area of Science:
- Hepatology
- Toxicology
- Cell Biology
Background:
- Apoptosis is a primary cellular response to liver injury from toxins, viral hepatitis, alcohol, and ischemia/reperfusion.
- Understanding apoptosis mechanisms is crucial for treating liver failure.
Purpose of the Study:
- To investigate the antiapoptotic effects of suramin in various liver injury models.
- To evaluate suramin's efficacy in preventing or mitigating liver damage.
Main Methods:
- Apoptosis was induced using APO-1 antibody in cell lines (Jurkat, HepG2).
- A mouse model of fulminant liver failure was established using Jo2 antibody.
- Apoptotic liver damage was induced in mice using D-galactosamine and endotoxin.
- Suramin's effects were assessed by survival rates, serum aminotransferase levels, liver appearance, and apoptosis levels.
- Necrotic cell death was evaluated in a rat liver transplantation model.
Main Results:
- Suramin exhibited antiapoptotic properties in APO-1-induced apoptosis in cell lines.
- Suramin protected 40% of mice from death in the Jo2-induced liver failure model and delayed mortality in others.
- Suramin significantly reduced D-galactosamine/endotoxin-induced liver damage, as evidenced by improved biochemical and histological markers.
- Suramin did not inhibit necrotic cell death in the rat liver transplantation model.
Conclusions:
- Suramin effectively inhibits apoptosis in multiple liver injury models.
- Suramin demonstrates therapeutic potential in mitigating liver damage caused by apoptosis.
- Targeting apoptosis with suramin or similar agents warrants further investigation for liver failure treatment.
Related Concept Videos
Hepatic Encephalopathy
Antiprotozoal Agents

